Jonathan Young insider trades: Akero Therapeutics (AKRO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jonathan reports to the SEC
Open-market buys and sales
43 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | AKRO | ↓ Sell | 12,500 | $47.76 | $597K | Direct | Oct 3, 2025 (2d) |
| Sep 11, 2025 | AKRO | ↓ Sell | 586 | $43.02 | $25K | Direct | Sep 12, 2025 (1d) |
| Sep 2, 2025 | AKRO | ↓ Sell | 12,500 | $46.08 | $576K | Direct | Sep 4, 2025 (2d) |
| Aug 12, 2025 | AKRO | ↓ Sell | 12,500 | $47.79 | $597K | Direct | Aug 13, 2025 (1d) |
| Jun 18, 2025 | AKRO | ↓ Sell | 1,453 | $54.84 | $80K | Direct | Jun 20, 2025 (2d) |
| Jun 10, 2025 | AKRO | ↓ Sell | 2,493 | $53.99 | $135K | Direct | Jun 12, 2025 (2d) |
| Mar 12, 2025 | AKRO | ↓ Sell | 607 | $44.88 | $27K | Direct | Mar 14, 2025 (2d) |
| Mar 4, 2025 | AKRO | ↓ Sell | 50,000 | $44.86 | $2.2M | Direct | Mar 5, 2025 (1d) |
| Feb 3, 2025 | AKRO | ↓ Sell | 10,000 | $53.81 | $538K | Direct | Feb 5, 2025 (2d) |
| Jan 2, 2025 | AKRO | ↓ Sell | 10,000 | $28.03 | $280K | Direct | Jan 6, 2025 (4d) |
| Dec 10, 2024 | AKRO | ↓ Sell | 2,503 | $30.79 | $77K | Direct | Dec 12, 2024 (2d) |
| Dec 2, 2024 | AKRO | ↓ Sell | 10,000 | $32.13 | $321K | Direct | Dec 4, 2024 (2d) |
| Nov 1, 2024 | AKRO | ↓ Sell | 50,716 | $31.57 | $1.6M | Direct | Nov 5, 2024 (4d) |
| Oct 14, 2024 | AKRO | ↓ Sell | 40,000 | $30.15 | $1.2M | Direct | Oct 16, 2024 (2d) |
| Oct 1, 2024 | AKRO | ↓ Sell | 10,000 | $28.18 | $282K | Direct | Oct 3, 2024 (2d) |
| Sep 10, 2024 | AKRO | ↓ Sell | 568 | $26.18 | $15K | Direct | Sep 13, 2024 (3d) |
| Sep 3, 2024 | AKRO | ↓ Sell | 5,000 | $26.72 | $134K | Direct | Sep 5, 2024 (2d) |
| Aug 1, 2024 | AKRO | ↓ Sell | 5,000 | $26.75 | $134K | Direct | Aug 2, 2024 (1d) |
| Jul 1, 2024 | AKRO | ↓ Sell | 5,000 | $23.40 | $117K | Direct | Jul 2, 2024 (1d) |
| Jun 11, 2024 | AKRO | ↓ Sell | 2,516 | $22.64 | $57K | Direct | Jun 13, 2024 (2d) |
| Jun 3, 2024 | AKRO | ↓ Sell | 5,000 | $19.29 | $96K | Direct | Jun 5, 2024 (2d) |
| May 1, 2024 | AKRO | ↓ Sell | 5,000 | $20.15 | $101K | Direct | May 2, 2024 (1d) |
| Apr 1, 2024 | AKRO | ↓ Sell | 4,600 | $24.33 | $112K | Direct | Apr 3, 2024 (2d) |
| Apr 1, 2024 | AKRO | ↓ Sell | 400 | $25.02 | $10K | Direct | Apr 3, 2024 (2d) |
| Mar 13, 2024 | AKRO | ↓ Sell | 651 | $28.33 | $18K | Direct | Mar 15, 2024 (2d) |
| Dec 27, 2023 | AKRO | ↓ Sell | 5,414 | $24.00 | $130K | Direct | Dec 29, 2023 (2d) |
| Dec 14, 2023 | AKRO | ↓ Sell | 543 | $20.76 | $11K | Direct | Dec 18, 2023 (4d) |
| Nov 17, 2023 | AKRO | ↓ Sell | 30,000 | $14.68 | $440K | Direct | Nov 21, 2023 (4d) |
| Oct 2, 2023 | AKRO | ↓ Sell | 490 | $51.10 | $25K | Direct | Oct 4, 2023 (2d) |
| Sep 13, 2023 | AKRO | ↓ Sell | 562 | $50.34 | $28K | Direct | Sep 25, 2023 (12d) |
| Jun 13, 2023 | AKRO | ↓ Sell | 538 | $55.16 | $30K | Direct | Jun 15, 2023 (2d) |
| Jan 3, 2023 | AKRO | ↓ Sell | 8,777 | $54.64 | $480K | Direct | Jan 5, 2023 (2d) |
| Dec 27, 2022 | AKRO | ↓ Sell | 12,500 | $49.57 | $620K | Direct | Dec 28, 2022 (1d) |
| Oct 25, 2022 | AKRO | ↓ Sell | 12,500 | $44.72 | $559K | Direct | Oct 27, 2022 (2d) |
| Nov 4, 2021 | AKRO | ↓ Sell | 25,000 | $24.28 | $607K | Direct | Nov 5, 2021 (1d) |
| Sep 1, 2021 | AKRO | ↓ Sell | 12,500 | $24.04 | $301K | Direct | Sep 3, 2021 (2d) |
| Jun 1, 2021 | AKRO | ↓ Sell | 3,055 | $26.24 | $80K | Direct | Jun 2, 2021 (1d) |
| May 3, 2021 | AKRO | ↓ Sell | 3,055 | $30.56 | $93K | Direct | May 4, 2021 (1d) |
| Apr 1, 2021 | AKRO | ↓ Sell | 3,055 | $28.75 | $88K | Direct | Apr 5, 2021 (4d) |
| Mar 1, 2021 | AKRO | ↓ Sell | 3,055 | $30.48 | $93K | Direct | Mar 2, 2021 (1d) |
| Feb 1, 2021 | AKRO | ↓ Sell | 3,055 | $29.24 | $89K | Direct | Feb 2, 2021 (1d) |
| Jan 8, 2021 | AKRO | ↓ Sell | 10,000 | $28.12 | $281K | Direct | Jan 11, 2021 (3d) |
| Jan 4, 2021 | AKRO | ↓ Sell | 3,060 | $25.29 | $77K | Direct | Jan 6, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Jonathan Young's insider trades
Jonathan Young is Chief Operating Officer at Akero Therapeutics (AKRO). Since Jan 4, 2021, Jonathan has reported no open-market purchases and 43 sales worth $13.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (18 filings), grants and awards (10 filings), shares returned to the company (1 filing), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKRO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.